Posts by Cyril H. Benes, PhD
-
Combined EGFR/FGFR Inhibitor Therapy Proposed for FGFR2-Positive Intrahepatic Cholangiocarcinoma
By analyzing patient-derived models of FGFR2 fusion–positive intrahepatic cholangiocarcinoma, scientists at the Mass General Cancer Center determined feedback activation of EGFR-dependent signaling limits the efficacy of FGFR inhibitors and combined EGFR/FGFR inhibition may be a therapeutic solution.
Biography
Cyril H. Benes, PhD, is principal investigator of the Benes Lab at the Mass General Cancer Center of Massachusetts General Hospital.
Mass General Brigham Cancer Institute
Mass General Brigham Cancer Institute unites leading experts and resources across our academic medical centers, making it one of the nation’s top providers of cancer care.